The US Food and Drug Administration (FDA) has granted approval for AstraZeneca‘s Farxiga (dapagliflozin) for the treatment of paediatric patients aged 10 years and above with type-2 diabetes (T2D)

The approval is a significant milestone, expanding the medication’s use to improve glycaemic control in children beyond its previous adult-only indication.

The FDA’s decision was based on the randomised, double-blind, placebo-controlled T2NOW Phase III trial.

The study assessed the efficacy and safety of dapagliflozin as an additional treatment for children and adolescents already taking metformin, insulin or both.

Participants were assigned to receive either dapagliflozin, saxagliptin or a placebo.

The trial’s primary goal was to observe the change in A1C (haemoglobin) levels after 26 weeks compared to placebo for both dapagliflozin and saxagliptin.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Secondary objectives included monitoring fasting plasma glucose levels and the percentage of patients achieving an A1C level below 7%.

Trial results showed a significant decrease in A1C for patients treated with Farxiga versus those given a placebo.

The adjusted mean change in A1C was -0.62% for Farxiga compared to +0.41% for the placebo group.

Farxiga demonstrated a clinically meaningful improvement in glycaemic control for children and adolescents with T2D.

The asset has also been approved for paediatric patients aged 10 years and above with T2D in 56 countries, based on the T2GO Phase III trial.

Further regulatory submissions and market evaluations are underway to determine additional rollout plans.

In addition to its use in diabetes management, Forxiga is approved in more than 100 countries for treating heart failure across the full ventricular ejection fraction range and chronic kidney disease in adults.

AstraZeneca BioPharmaceuticals Business Unit executive vice-president Ruud Dobber stated: “The prevalence of type-2 diabetes continues to rise in children and adolescents, yet oral treatment options have remained limited for this population.

“The approval represents an important milestone for paediatric patients living with type-2 diabetes in the US, extending this medicine’s potential benefits to even more patients facing high unmet needs and reinforcing AstraZeneca’s commitment to delivering innovative treatments across cardiovascular, renal and metabolic diseases.”

The latest development comes after AstraZeneca‘s supplemental new drug application for Tagrisso obtained FDA priority review for unresectable Stage III epidermal growth factor receptor-mutated non-small cell lung cancer after chemoradiotherapy.